FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat (FG-4592), is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis.

San Francisco, US
Size (employees)
364 (est)+4%
FibroGen was founded in 1993 and is headquartered in San Francisco, US

FibroGen Office Locations

FibroGen has office in San Francisco
San Francisco, US

FibroGen Metrics

FibroGen Summary

Market capitalization

$1.6 b

Closing share price

FibroGen's current market capitalization is $1.6 b.

FibroGen Financials

FibroGen's revenue is $179.6 m in FY, 2016
FY, 2016


$179.6 m

Net Income

($61.7 m)

FibroGen Market Value History

FibroGen Company Life

You may also be interested in